Sign in with your email address username.


[Comment] In-stent restenosis treatment: quest for the best device

European guidelines recommend that drug-eluting stents (DES) should be selected as the default strategy for interventional treatment of de-novo coronary lesions,1 in view of the substantial reduction of in-stent restenosis and late revascularisation achieved with this therapeutic option as compared with other treatments. Because of the widespread use of DES in Europe, ischaemia related to in-stent restenosis is now a rare occurrence. Recruitment of patients into randomised clinical trials to assess the most appropriate treatment in this setting has, therefore, become difficult, resulting in small or underpowered studies, mainly based on non-clinical endpoints.